MilliporeSigma Advances Cell Analysis with New Benchtop Flow Cytometer with Camera Detection

MilliporeSigma today launched its new CellStream™ benchtop flow cytometry system, a compact, customizable flow cytometer that uses a camera for detection. Its unique optics system and design provide...

27 Apr 2018 | Burlington, Massachusetts, United States of America
  • Highly sensitive optical system based on patented technology unique to MilliporeSigma’s Amnis® flow cytometers
  • Configurable, 7-laser capacity to meet researchers’ evolving needs
  • Laser upgrades quickly performed in lab with no downtime

MilliporeSigma today launched its new CellStream™ benchtop flow cytometry system, a compact, customizable flow cytometer that uses a camera for detection. Its unique optics system and design provide researchers with unparalleled sensitivity and flexibility when analyzing cells and submicron particles.

“Researchers increasingly require more power and agility in their labs and research capabilities,” said Jean-Charles Wirth, head of Applied Solutions at MilliporeSigma. “MilliporeSigma’s new CellStream™ flow cytometry system expands the limits of sensitivity, allowing scientists to tailor their instrument to their needs in immunology, cancer research and many other areas.”

The CellStreamTM system’s Amnis® time-delay integration and camera technology rapidly captures low-resolution cell images and converts them to high-throughput intensity data with enhanced fluorescence sensitivity. The new system can be used in a wide variety of research areas, including exosome research, where it can identify small populations unable to be seen on other cytometers.

MilliporeSigma developed this new technology with the same patent-protected optics system as its Amnis® flow cytometers, which are used in academic, biotech and pharmaceutical cell analysis and research applications.

The CellStream™ flow cytometry system offers multiple innovative features, including:

  • Fully customizable 7-laser capacity provides unparalleled versatility and the capability to obtain up to 22 detection channels.
  • Patent-protected TDI sensor and camera technology enables high fluorescence sensitivity.
  • The system may be fully and quickly upgraded on-site to add more lasers if needed.
  • Standard 96-well plate auto-sampler is available on all instruments to capture high-throughput intensity data.
  • Event gallery allows visual verification of cell populations and helps troubleshoot.

The new CellStream™ system expands MilliporeSigma’s portfolio of innovative flow cytometry platforms. 

Downloads

  • Advanced-cell-analysis-with-new-benchtop-flow-cytometer-US.pdf
For more information, contact Karen Tiano

All Merck KGaA, Darmstadt, Germany, press releases are distributed by e-mail at the same time they become available on the EMD Group Website. In case you are a resident of the USA or Canada please go to www.emdgroup.com/subscribe to register for your online subscription of this service as our geo-targeting requires new links in the email. You may later change your selection or discontinue this service.

About Merck KGaA, Darmstadt, Germany

Merck KGaA, Darmstadt, Germany, a leading science and technology company, operates across life science, healthcare and electronics. Around 60,000 employees work to make a positive difference to millions of people’s lives every day by creating more joyful and sustainable ways to live. From advancing gene editing technologies and discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – the company is everywhere. In 2021, Merck KGaA, Darmstadt, Germany, generated sales of € 19.7 billion in 66 countries.

The company holds the global rights to the name and trademark “Merck” internationally. The only exceptions are the United States and Canada, where the business sectors of Merck KGaA, Darmstadt, Germany, operate as MilliporeSigma in life science, EMD Serono in healthcare, and EMD Electronics in electronics. Since its founding in 1668, scientific exploration and responsible entrepreneurship have been key to the company’s technological and scientific advances. To this day, the founding family remains the majority owner of the publicly listed company.

Related News

  1. Press Releases

    Merck KGaA, Darmstadt, Germany Aims to Double R&D Productivity in Oncology ...

    Merck KGaA today shared updates on the company’s healthcare research and development strategy, aimed at doubling R&D productivity.

    2022/11/21